Vaccine Breakthrough Impact: Social media conversations have intensified around Tempus AI after the Phase 3 success reported by Moderna and Merck in personalized cancer vaccines. Observers point to the stock's notable gains as the development validates broader applications in precision oncology and sequencing technologies.
Growth Metrics Highlighted: Participants frequently reference recent revenue increases and new data licensing agreements as evidence of expanding market position. The intersection of artificial intelligence with healthcare diagnostics continues to draw attention in ongoing threads.
Platform Positioning Discussed: Analysts on social media emphasize Tempus's data capabilities and recent acquisitions as factors that could support long-term ecosystem involvement. Overall tone reflects sustained interest in the company's trajectory following these developments.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI Insider Trading Activity
Tempus AI insiders have traded $TEM stock on the open market 103 times in the past 6 months. Of those trades, 0 have been purchases and 103 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 70 sales selling 1,319,926 shares for an estimated $68,723,000.
- RYAN FUKUSHIMA (CEO, Data) has made 0 purchases and 13 sales selling 141,747 shares for an estimated $7,246,870.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 4 sales selling 71,224 shares for an estimated $3,808,830.
- ANDREW POLOVIN (EVP, Chief Legal Officer) has made 0 purchases and 3 sales selling 38,778 shares for an estimated $1,926,215.
- THOMAS EDWARD SCHOENHERR (CEO, Diagnostics) has made 0 purchases and 8 sales selling 18,894 shares for an estimated $999,621.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 10,291 shares for an estimated $487,733.
- JENNIFER A DOUDNA sold 2,673 shares for an estimated $147,015
- DAVID R EPSTEIN has made 0 purchases and 2 sales selling 620 shares for an estimated $28,408.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Tempus AI Revenue
Tempus AI had revenues of $382.5M in Q2 2026. This is an increase of 21.56% from the same period in the prior year.
You can track TEM financials on Quiver Quantitative's TEM stock page.
You can access data on TEM stock through the Quiver Quantitative API.
Tempus AI Hedge Fund Activity
We have seen 281 institutional investors add shares of Tempus AI stock to their portfolio, and 243 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 4,989,062 shares (+inf%) to their portfolio in Q2 2026, for an estimated $289,016,361
- GC WEALTH MANAGEMENT RIA, LLC removed 4,199,843 shares (-63.5%) from their portfolio in Q2 2026, for an estimated $243,296,904
- GOLDMAN SACHS GROUP INC added 2,483,910 shares (+194.4%) to their portfolio in Q2 2026, for an estimated $143,892,906
- CITADEL ADVISORS LLC added 1,911,096 shares (+317.8%) to their portfolio in Q2 2026, for an estimated $110,709,791
- MORGAN STANLEY added 1,568,701 shares (+75.3%) to their portfolio in Q2 2026, for an estimated $90,874,848
- BANK OF AMERICA CORP /DE/ added 1,502,992 shares (+362.4%) to their portfolio in Q2 2026, for an estimated $87,068,326
- D. E. SHAW & CO., INC. removed 1,180,315 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $68,375,647
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Tempus AI Government Contracts
We have seen $29,358,042 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Tempus AI Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 7 analysts offer price targets for $TEM in the last 6 months, with a median target of $64.0.
Here are some recent targets:
- Gene Mannheimer from Freedom Capital Markets set a target price of $59.0 on 07/01/2026
- Ryan MacDonald from Needham set a target price of $75.0 on 06/01/2026
- Mark Massaro from BTIG set a target price of $80.0 on 06/01/2026
- Yi Chen from HC Wainwright & Co. set a target price of $64.0 on 05/11/2026
- Dan Brennan from TD Cowen set a target price of $68.0 on 05/06/2026
- Tycho Peterson from Jefferies set a target price of $35.0 on 04/13/2026
- Subbu Nambi from Guggenheim set a target price of $60.0 on 03/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
